Although 1 in 10 patients has a penicillin allergy noted in their
medical record, many were misdiagnosed as children or are no longer
allergic, the authors write.
"The 'penicillin allergy' label affects the antibiotic options
available to patients, resulting in the use of alternative and often
less effective antibiotics that can expose patients to unnecessary
risks, so it is important for patients to know their true penicillin
allergy status," Dr. Erica Shenoy of Massachusetts General Hospital
in Boston, coauthor of the patient resource, told Reuters Health.
About 32 million Americans have a recorded penicillin allergy, but
about 95 percent of them don't truly have the allergy, she said.
"When physicians believe they cannot prescribe penicillin or a
related drug, they often turn to what we call 'broader spectrum'
antibiotics," she said in an email. "While these antibiotics may
treat the patient, there is a cost, including increased risk of
developing infections and the potential for antibiotic resistance."
Available for free, the new patient page (https://bit.ly/2RR5NLk)
offers practical answers to questions about penicillin and
highlights misconceptions about the allergy. It also includes
details about the allergy tests that can determine whether a person
really is allergic to penicillin and related drugs.
The patient page is based on a report published in the same issue of
JAMA that outlines recommendations for doctors to evaluate and
manage penicillin allergies in their patients.
The authors explain that penicillin belongs to a group of drugs
called beta-lactam antibiotics that can be given by mouth or
injection to treat bacterial infections. Most patients with a
documented allergy were diagnosed as children because of a rash that
was likely caused by a virus rather than an allergy. For those who
did have a true penicillin allergy, about 8 in 10 are no longer
allergic after a 10-year period.
Another source of confusion is that the term "allergy" is often used
to also include intolerances and side effects, which are not the
same thing. An allergy includes an immunological response that
typically occurs with each exposure, versus a side effect or rash
that happens one time, said the other coauthor of the patient
resource, Dr. Kimberly Blumenthal of Harvard Medical School in
Boston.
[to top of second column] |
"Another common misconception is that it runs in families," she told
Reuters Health by email. "While there certainly are types of drug
reactions that have a familial or genetic component, the penicillin
allergy generally does not."
If patients have a question about their penicillin allergy, they
should talk to their doctor about a new evaluation. Skin testing may
be helpful for patients with a history of hives, rash, swelling or
shortness of breath. If an initial skin prick test is negative, a
second intradermal test places the penicillin under the skin and is
examined after 15-20 minutes. If that test is also negative, doctors
may test an oral dose of penicillin while observing the patient to
monitor the reaction.
For patients who have "low-risk" reactions such as headache, nausea,
vomiting, itching or a family history of the allergy, skin tests may
not be necessary, and the doctor may start with an oral dose of
penicillin under observation.
"We should do what we can to remove these labels of penicillin
allergy because it leads to better healthcare outcomes," said Dr.
David Lang of the Cleveland Clinic in Ohio. Lang, who wasn't
involved with this patient resource, is president-elect of the
American Academy of Allergy, Asthma and Immunology.
"I'd advise patients to be proactive regarding the possibility that
they may no longer be allergic to penicillin," he told Reuters
Health by phone. "Even though you may have had an adverse reaction
in the past, an evaluation may lead to being de-labeled and could be
in your best interest."
SOURCE: https://bit.ly/2RR5NLk JAMA, online January 15, 2019.
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |